211 related articles for article (PubMed ID: 9250189)
1. Efficacy of troglitazone measured by insulin resistance index.
Nagasaka S; Iwamoto Y; Ishikawa S; Kuzuya T; Saito T
Lancet; 1997 Jul; 350(9072):184. PubMed ID: 9250189
[No Abstract] [Full Text] [Related]
2. Learning to use troglitazone.
Riddle MC
Diabetes Care; 1998 Sep; 21(9):1389-90. PubMed ID: 9727881
[No Abstract] [Full Text] [Related]
3. New diabetes drug targets insulin resistance.
Am J Health Syst Pharm; 1997 Mar; 54(6):623, 625. PubMed ID: 9075488
[No Abstract] [Full Text] [Related]
4. Troglitazone: a new antihyperglycemic agent.
Vidt DG; Speerhas RA; Reddy SS
Cleve Clin J Med; 1997 May; 64(5):238-40. PubMed ID: 9149473
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone and small low-density lipoprotein in type 2 diabetes.
Hirano T; Yoshino G; Kazumi T
Ann Intern Med; 1998 Jul; 129(2):162-3. PubMed ID: 9669982
[No Abstract] [Full Text] [Related]
6. New directions in treating insulin resistance.
Reusch JE
Hosp Pract (1995); 1995 Sep; 30(9):9-10. PubMed ID: 7559840
[No Abstract] [Full Text] [Related]
7. Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Tack CJ; Smits P; DeMacker PN; Stalenhoef AF
Diabetes Care; 1999 Oct; 22(10):1752-3. PubMed ID: 10526754
[No Abstract] [Full Text] [Related]
8. [Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Westerbacka J; Yki-Järvinen H
Duodecim; 1997; 113(19):1847-8. PubMed ID: 10892078
[No Abstract] [Full Text] [Related]
9. [A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody].
Takahashi S; Oida K; Miyamori I
Nihon Ronen Igakkai Zasshi; 2000 Apr; 37(4):344-8. PubMed ID: 10917034
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic approaches to reversing insulin resistance.
Sonnenberg GE; Kotchen TA
Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):551-5. PubMed ID: 9818203
[TBL] [Abstract][Full Text] [Related]
11. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
12. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
13. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
14. Troglitazone directly increases HDL cholesterol levels.
Nozue T; Michishita I; Minagawa F; Genda A
Diabetes Care; 1999 Feb; 22(2):355-6. PubMed ID: 10333957
[No Abstract] [Full Text] [Related]
15. A treatment for Mr WP: thiazolidinediones after troglitazone.
Montague CT
Diabet Med; 2002; 19 Suppl 1():7-9. PubMed ID: 11871423
[No Abstract] [Full Text] [Related]
16. Effects of troglitazone on insulin sensitivity.
Henry RR
Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
[TBL] [Abstract][Full Text] [Related]
17. Effect of troglitazone in type 2 diabetes mellitus.
Gorson DM
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
[No Abstract] [Full Text] [Related]
18. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
19. Effect of troglitazone in type 2 diabetes mellitus.
Rusk MH
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
[No Abstract] [Full Text] [Related]
20. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]